Key Points Immuron completes first meeting with FDA on development of IMM-124E as product to specifically prevent Travelers’ Diarrhea (TD) Phase 3 clinical trial of IMM-124E to prevent TD planned for 2020 Previous clinical trial data on IMM-124E from earlier studies...
Enrollment Rate Exceeds Expectation, Suggesting High Unmet Need and Anticipation for Bermekimab in HS AUSTIN, Texas, Nov. 19, 2019 (GLOBE NEWSWIRE) — XBiotech Inc. (NASDAQ: XBIT) today announces rapid enrollment in its randomized, double-blind,...
– MOMENTUM trial designed to confirm the unique benefits of momelotinib on all three hallmarks of myelofibrosis: symptoms, anemia and enlarged spleen — Targeting enrollment of 180 symptomatic and anemic patients previously treated with a JAK inhibitor –-...
With the French Regulatory Approval by ANSM, the clinical trial is fully approved in 15 countries The clinical trial with once a day oral dosing is being conducted in 232 patients with moderate to severe ulcerative colitis in about 150 study sites As announced during...
Email
Text